Butterfly Pivotal Study

Exclusion Criteria

• •1. Known sensitivity to Nickel.
• •2. Current urinary retention
• •3. Urinary stress incontinence (sphincter)
• •4. Biopsy of the prostate within the last 6 weeks
• •5. Baseline PSA \> 10 ng/mL or confirmed or suspected prostate cancer. Patients with a PSA level above 2.5 ng/mL, in which free PSA is \< 25% of total PSA in whom cancer was not ruled out by biopsy.
• •6. Chronic prostatitis, recurrent prostatitis, chronic pelvic pain syndrome (CPPS), or painful bladder syndrome within the past 12 months
• •7. Obstructing intraprostatic median lobe (e.g., more than 10mm intravesical prostatic protrusion).
• •8. Urethral stricture, meatal stenosis, or bladder neck stricture - either current or recurrent.
• •9. Anatomical anomalies that will not accommodate the retractor, as determined by cystoscopy (e.g., prostatic urethral length to height geometry, absence of bladder neck)
• •10. Prior surgery or minimal invasive procedure of prostate (brachytherapy and PAE patients are not excluded if they show significant obstruction in urodynamic test and cystoscopy shows no significant fibrosis).
• •11. Currently active bladder tumor or intravesical instillation.
• •12. History of other diseases causing voiding dysfunction including urinary retention (e.g., uncontrolled diabetes, diagnosis of neurogenic or atonic bladder, Parkinson's disease, multiple sclerosis, etc.).
• •13. Suspected Neurogenic or atonic urinary bladder.
• •14. Suspected Polyuria/Nocturnal Polyuria.
• •15. Suspected overactive bladder
• •16. High bladder neck with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction as determined by the Investigator
• •17. Urethral pathology: diverticula, strictures, tumors, fistula.
• •18. Acute clinically Significant urinary tract infection.
• •19. Uncontrolled bleeding disorders.
• •20. Active stone disease (urinary stone increase in size during the last 3 months/ stone passage during the last 3 months/ presence of cystolithiasis)
• •21. Taking 5 alpha reductase inhibitors within 6 months of baseline evaluation
• •22. Taking one of the following within 2 weeks of baseline evaluation:
• •1. alpha-blockers,
• •2. imipramine,
• •3. anticholinergics,
• •4. Phosphodiesterase-5 Enzyme Inhibitors (Tadalafil) in doses for BPH,
• •5. Beta-3 adrenergic receptor agonist (Mirabegron),
• •23. Taking androgens, unless eugonadal state for at least 2 months or greater as documented by the Investigator
• •24. Taking Gonadotrophin releasing hormone analogues within 12 months of baseline evaluation
• •25. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:
• •phenylephrine, or, pseudoephedrine,
• •26. One of the following baseline test results, taken from a single uroflowmetry reading:
• •* Urinary volume void ≤ 125mL (pre-bladder urinary volume of ≥ 150 mL required),
• •* Peak urinary flow rate (Qmax) of ≤ 5 ml/second and \> 15 mL/second,
• •* Post- void residual volume (PVR) \> 250 mL
• •27. Inmates, patient with physical, psychological (such as developmentally delayed adults), or medical impairment that might prevent study completion or would confound study results (including patient questionnaires) in the judgment of the Investigator
• •28. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.